Tropical Splenic Lymphoma: Splenic Marginal Zone Lymphoma or Distinct Entity?.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4654-4654
Author(s):  
Elizabeth A. Stephens ◽  
Imelda Bates ◽  
George Bedu-Addo ◽  
Ivy Ekem ◽  
Yvonne Dei ◽  
...  

Abstract In the early 1990’s we described a series of patients from Kumasi, Ghana, West Africa who appeared to have a distinctive lymphoproliferative disorder (LPD) characterised by massive splenomegaly and lymphocytosis with characteristic morphology. At the time this was termed tropical splenic lymphoma (TSL). These patients, in contrast to most patients with LPD’s, tended to be female and relatively young and were frequently diagnosed as having hyper-reactive malarial splenomegaly. An aetiological role for chronic malaria infection has been postulated but remains as yet unproven. Only limited phenotypic and genotypic characterisation of such patients has been possible previously. Given the clinical features and potential aetiological role for malaria infection we wanted to determine whether TSL represented a distinct entity or may be more appropriately considered as splenic marginal zone lymphoma (SMZL). We have therefore evaluated the clinical, immunophentypic and genotypic features of 19 pts (median age 63 years, range 40–78) with a clinical diagnosis of TSL. Peripheral blood, bone marrow aspirate and trephine biopsies were obtained in all patients and the laboratory assessment were performed in the HMDS laboratory, Leeds, UK as part of an on-going collaborative project investigating lymphomas in Ghana. 14 of the 19 patients (73%) were female and all had significant splenomegaly (median length below the costophrenic margin of 17cm, range 6–30 cm). 5/19 patients (26%) had lymphadenopathy and 17/19 patients (89%) had a lymphocytosis - median 30.1×09/l (range 5.4×09/l - unrecordable). Bone marrow infiltration was evident in the trephine biopsies of all patients and was extensive in the majority. Immunophenotyping was performed primarily by immunohistochemistry on the trephine sections although flow cytometry was possible in a proportion of patients. The majority of cases were characterised by a CD5− CD10− CD20+ CD23− CD79+ BCL2+ BCL6− MUM1/IRF4- cyclin D1- immunophenotype. The rate of cell proliferation was low in all cases. FISH studies were performed and these demonstrated del7q31 in 4/18 cases and del6q21 in 1/19 cases. There was no evidence of the t(11;14), t(9;14) or MALT1 rearrangements. IgH sequence analysis was also performed in 16 cases and this demonstrated that 9/16 cases (56%) were germline (>98% homology) and 7/16 (44%) were mutated (<98% homology). Within the mutated group the overall mutation load appeared to be relatively low - median 3.3% (range 3–6%) with most utilising the VH3 family genes. This is the first detailed clinicopathological assessment of patients with a clinical diagnosis of TSL. These patients clearly have some pathological features seen in patients with SMZL such as a CD5− CD10− CD23− immunophenotype, 7q31 deletions and cases with both germline and mutated Ig genes. Definitive phenotypic and genotypic features are unfortunately lacking in SMZL and it remains uncertain whether patients with a clinical diagnosis of TSL should be considered as having SMZL.

2006 ◽  
Vol 76 (5) ◽  
pp. 392-398 ◽  
Author(s):  
Achille Pich ◽  
Flavio Fraire ◽  
Alessandro Fornari ◽  
Laura Davico Bonino ◽  
Laura Godio ◽  
...  

2019 ◽  
Vol 37 (2) ◽  
pp. 219-222 ◽  
Author(s):  
Maria K. Angelopoulou ◽  
Theodoros P. Vassilakopoulos ◽  
Eliana Konstantinou ◽  
George Boutsikas ◽  
John V. Asimakopoulos ◽  
...  

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3993-3993
Author(s):  
Susanna S Gaykazyan ◽  
Nalini Janakiraman ◽  
Philip Kuriakose ◽  
Koichi Maeda ◽  
Tareq Hammour

Abstract SMZL is an indolent B-cell malignancy accounting for 1–2% of chronic lymphoid leukemia found on bone marrow examination and up to 25% of low-grade B-cell neoplasms in splenectomy patients. Aggressive transformation of SMZL rarely occurs. It usually presents as an incidental finding or with symptoms of splenomegaly and anemia. There is still no reliable clinical or biological scoring system for prognostic stratification. We reviewed pathology reports of 41 splenectomized patients at HFHS from 1994 to 2007 and identified 14 patients with splenic marginal zone lymphoma (SMZL). The reasons for splenectomy were symptoms of splenomegaly in all 14 patients, anemia in 13 patients, thrombocytopenia in 12 patients, AIHA in 4 patients, splenic laceration in one patient. We report here the demographics, clinical course and pathology review of these patients. The median age of patients was 77.8 years. There were 7 male and 7 female patients. ECOG performance status was 0–1 in 12(86%), and 2 in 2(14%). Of the 14 patients, 8(57%) were at Ann Arbor stage IV, 1(7%) was at stage III, 4(29%) were at stage II, and 1(7%) at stage I. LDH was above normal in 9(64%) patients B-symptoms were observed in 1(7%). Bone marrow involvement was documented in 8(57%) of the patients. Anemia in 13(93%), thrombocytopenia in 12(86%), AIHA in 4(29%). IPI score was 1–2 in 5(36%), and score 3–4 in 9(64%) of the patients. Median weight of the spleen was 1235 gm. Bone marrow cytogenetics were abnormal in 4(29%) cases. Following splenectomy, cytopenias resolved completely or partially (CR/PR) in 13(93%) patients. Bacterial infections were observed in 4(29%) patients and 2(14%) died of infectious complications. Progressive disease requiring additional systemic therapy was documented in 5(36%) patients. Total of 5(36%) patients died. One secondary to NSLC, 1(7%) of urothelial carcinoma, 1(7%) secondary to hypercalcemia, 2(14%) due to bacterial sepsis. Patients were followed up to 139 months (with median follow-up time of 42 months). The estimated median overall survival (OS) for this group was 116.5 months (9.7 years), the median progression-free survival (PFS) was 91 months (7.6 years). The Kaplan Meier method was used to calculate these estimates. A simple median was calculated for the sample median. In summary, we report the course of 14 patients with SMZL who underwent splenectomy for symptomatic disease. Only 5(36%) required systemic therapy following splenectomy. No death was attributed to progressive SMZL. Overall course was indolent even after splenectomy. Estimated OS was 116.5 months (9.7 years), PFS - 91 month (7.6 years).


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 5200-5200
Author(s):  
Hunan Julhakyan ◽  
Aminat Magomedova ◽  
Sergey K Kravchenko ◽  
Tatyana N Obukhova ◽  
Rima Samoylova ◽  
...  

Abstract Abstract 5200 Background: Splenic marginal zone lymphoma (SMZL) is a well recognized B-cell neoplasm which is characterized by splenomegaly, bone marrow involvement, immunologically by typical phenotype of marginal zone cells. The most frequent cytogenetic findings are involvement of chromosomes 1, 3, 7(usually deleted in 7q) and 8. The t(14;19)(q32;q13) is a rare cytogenetic abnormality with bcl-3 rearrangement that has been reported in other B-cell lymphomas. Aims: To describe the clinical, morphological, immunophenotypic findings in SMZL associated with t(14;19)(q32;q13). Methods and results: In Hematological Research Centre, Moscow between January 2001 and May 2011 three cases SMZL with t(14;19)(q32;q13) were identified. All patients were males with age 51, 58, 67 y.o. Lymphoma presented with B-symptoms, high level of lactate dehydrogenase (LDH), hepatosplenomegaly and regional lymphadenopathy (enlarge splenic hilar lymphnodes). The hemoglobin was 92 g/l, 110 g/l, 122 g/l. All patients had normal count of leukocytes with an absolute lymphocytosis (lymphocytes count 72 × 109 g/l, 79 × 109 g/l, 83 × 109/l) and thrombocytopenia. Morphological examination of peripheral blood and bone marrow lymphocytes showed that all lymphocytes are atypical with wide cytoplasm and nuclear indentation. In all cases there was nodular type of bone marrow involvement, composed of majority medium sized cells. Immunophenotypic analysis has shown the expression of mature B-cells antigens (CD19, CD20, CD22, FMC7, sIg) and absence of ÑD10, CD23, CD5, CD43, CyclinD1. Two patients were treated with CHOP-regimen without any response. They progressed with spleen enlargement and decreased of thrombocytes counts. All 3 patients undergo splenectomy. Weight of spleen was 1800 g, 2083 g, 2850 g. Splenic section generally show massive nodular pattern (involvement of the white and red pulp) associated with diffuse invasion of the sinuses. In all cases discovered high Ki-67. All patients demonstrated progression after splenectomy during 3–6 months that was characterized by increase of leukocytes count (range 45,4 – 101,8 × 109 /l), high level of LDH, appearance of peripheral and visceral lymph nodes. Considering the increase leucocytes, presence of lymphadenopathy in all cases CHOP, FMC regimen were used. All patients died of disease progression and infectious complications. Time of observation was 21, 30, 34 months. Conclusions: The t(14;19)(q32;q13)-positive SMZL is distinct variant which is characterized by rapid progression after splenectomy, poor responses to chemotherapy and short survival. So t(14;19)(q32;q13) may be regarded as a poor prognostic factor. Disclosures: No relevant conflicts of interest to declare.


2004 ◽  
Vol 44 (4) ◽  
pp. 381-386 ◽  
Author(s):  
V Franco ◽  
A M Florena ◽  
S Ascani ◽  
M Paulli ◽  
M Salvato ◽  
...  

2020 ◽  
pp. 29-33
Author(s):  
Alyona Polishchuk ◽  
Michael Zavelevich ◽  
Daniil Gluzman

The cytological and immunocytochemical features of the lymphocytes with villous morphology in peripheral blood and bone marrow in some B-lymphoproliferative disorders were studied. The diagnosis of hairy cell leukemia, a hairy cell leukemia variant, splenic marginal zone lymphoma and splenic diffuse red pulp small B-cell lymphoma was ascertained in accordance with the new revision of the WHO classification (2016). The neoplastic cells of hairy cell leukemia were determined by the presence of high tartrate resistant acid phosphatase (TRAP) activity. Cell surface expression of CD19, CD20 and CD21 antigens was detected. Also, the expression of CD25, CD103 and CD200, and in some cases cyclin D1, was found out. CD5, CD10 and CD23 were not detected. The immunophenotype of cells in splenic marginal zone lymphoma with villous processes also corresponded to the mature B cells. The expression of CD19, CD20 and CD21 was observed in all cases, CD11c – in 50% of patients, CD25 or CD5 – in 10% of patients. In 80% of patients, the pathologic cells did not show TRAP activity. In the bone marrow and peripheral blood cells of patients with diffuse red pulp lymphoma, TRAP activity was not detected. An immunophenotype in the hairy cell leukemia variant was different from those of classic HCL (CD19+CD20+CD22+CD103+CD11c+CD5–CD10–CD23–). Characterized immunophenotypical markers, which have differential diagnostic values in several forms of lymphoid tumors of B cell origin, will be important for the choice of treatment methods and prognosis


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 922-922
Author(s):  
Apostolia-Maria Tsimberidou ◽  
Daniel Catovsky ◽  
Ellen Schlette ◽  
Susan O’Brien ◽  
Hagop Kantarjian ◽  
...  

Abstract Purpose: The optimal management of splenic marginal zone lymphoma (SMZL) or marginal-zone leukemia/lymphoma (MZL) is controversial. We retrospectively assessed the clinical outcome of patients with SMZL/MZL treated with systemic therapy. Patients and Methods: Patients were assessed by the time of their first treatment at U. T. M. D. Anderson Cancer Center, Dept. of Leukemia (5/95 to 10/04). Diagnosis was confirmed in 70 patients by slide review. The indications for treatment were the same as those used for patients with CLL. Results: The median age was 64 years (range, 33–88); and 61% of patients had monoclonal gammopathy. The median number of CD20 molecules/cell was 65.2 x 103 (16–260 x 103). Of the patients who required systemic therapy, 26 were treated with immunotherapy (rituximab, 25; alemtuzumab, 1); 6 with chemoimmunotherapy (CI/T; rituximab combined with a fludarabine-based regimen); and 11 with chemotherapy (C/T). Ten patients had splenectomy, and 17 were in the observation group. The overall response rates were 88% (CR, 31%) in the immunotherapy group, 83% (CR, 17%) in the CI/T group, and 55% (CR, 18%) in the C/T group. The median follow-up was 2.7 years. Patients treated with immunotherapy +/− C/T had higher rates of overall and failure-free survival compared with those treated with C/T. Figure Figure In univariate analysis, the only factors predicting longer survival were age >60 years (p=0.01) and immunotherapy +/− chemotherapy (p=0.04). Seventeen (24%) of 70 patients had other malignancies prior to (n=8) or after (n=8) treatment of SMZL/MZL or both (n=1). Changes in bone marrow and blood counts in patients treated with rituximab (n=25) were compared with those of patients who had splenectomy as initial therapy (n=17, including 7 who had subsequent therapies). Rituximab resulted in the disappearance of a palpable spleen (median size, 6 cm; range 0–20cm) in 23 (92%) patients. Rituximab was superior to splenectomy in normalizing the white blood cell (WBC) counts (p<0.001) and absolute lymphocyte counts (ALC)(p<0.001). Splenectomy resulted in higher platelet counts compared with rituximab, but platelet counts remained within the normal range in all patients treated with rituximab. Hemoglobin levels and bone marrow cellularity did not reach statistical significance, but there was a trend towards a significantly lower proportion of lymphocytes in patients treated with rituximab (p=0.1). Conclusions: Rituximab with or without C/T induces durable remissions and prolongs survival in patients with SMZL/MZL, probably because CD20 molecules/cell are higher in SMZL/MZL than in CLL. Our data demonstrate that rituximab effectively controls SMZL, as evidenced by improvement in WBC and ALC and splenomegaly, and may be the treatment of choice, at least in older SMZL patients with comorbid diseases. Clinical trials of immunotherapy or CI/T are warranted.


Sign in / Sign up

Export Citation Format

Share Document